Taiwan teams up with NCI in lung cancer research
On September 27, 2017, a joint medical research team from the Taipei Veterans General Hospital and Yangming University announced that it has signed a memorandum of cooperation on the establishment of a cooperative laboratory with the David Schrump Thoracic and Gastrointestinal Oncology Branch at the Center for Cancer Research of the National Cancer Institute (NCI) of the United States with the help of the Stephen J. Solarz Memorial Fund to study lung cancer and its treatment.
Lung cancer has been the top killer of cancer patients in Taiwan for 7 consecutive years with an increase of about 1,000 new patients a year. Most of them being diagnosed are already in the mid to late stages of the disease and their five-year survival rate is only 30%.
Asians and Westerners differ greatly in their lung cancer genotype, in clinical characteristics, and in their reaction to anticancer drugs.
Asian lung cancer patients suffer mostly from mutation of the epidermal growth factor which occurs in nonsmoking females. Targeted anticancer treatment is more effective for such patients.
The cooperative laboratory will focus on the effects of lung cancer in racial differences to find new directions in targeted treatment and establish a guided multi-functional stem cell producing mechanism to strengthen immunotherapy by cultivating placenta stage blood cells to become T cells for use in immunotherapy to solve the bottlenecks encountered in genotype treatment of lung cancer.